Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Part of overall AMCP Nexus page

Program Description

Cardiovascular-kidney-metabolic (CKM) syndrome is a progressive, multi-system condition characterized by the coexistence of chronic kidney disease, metabolic dysfunction, and cardiovascular disease. With overlapping pathophysiology and compounding risks, CKM poses significant challenges in treatment selection, particularly when patients present with both cardiac and renal comorbidities. Sodium glucose cotransporter 2 (SGLT2) inhibitors have emerged as a cornerstone of therapy, demonstrating efficacy across glucose management, cardiovascular outcomes, and renal protection. However, with multiple agents available and variable data across patient populations, selecting the most appropriate treatment can be complex. This discussion will examine the latest clinical data on SGLT2 inhibitors, including their impact on disease progression, hospitalization, and mortality. It will also address the nuances of choosing therapy in patients with overlapping conditions and explore guideline-directed treatment strategies supported by real-world evidence. A case-based discussion will be included to illustrate how pharmacists can evaluate available options and advocate for access to cost-effective, evidence-based care that supports improved patient outcomes and system-wide value.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain cardiovascular-kidney-metabolic (CKM) syndrome and the importance of early identification, diagnosis, and prompt treatment to improve prognosis, including slowing the disease process and reducing complications.
• Apply the guideline recommendations for CKM syndrome, including heart failure and chronic kidney disease, and the data supporting the use of SGLT2 inhibitors in the care of patients with cardiorenal syndrome with or without diabetes.
• Determine an individualized treatment strategy integrating best practices using SGLT2 inhibitors for patients with CKM syndrome to promote quality care while efficiently allocating health care resources.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-365-H01-P. The activity is available for CE credit through November 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES, has the following relevant financial relationship with an ineligible company to disclose: Speakers Bureau: Xeris Pharmaceuticals.

Amanda Williams, PharmD, RPh, has the following relevant financial relationship with an ineligible company to disclose: Employee of a PBM: Gainwell Technologies (manage the preferred drug list (PDL) for state clients).

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:

www.pharmacytimes.org/terms